Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences Ltd. (ROIV)
:ROIV
Holding ROIV?
Track your performance easily
Earnings Data
Report Date
Feb 17, 2025TBA Not Confirmed
Period Ending
2024 (Q3)Consensus EPS Forecast
-0.25Last Year’s EPS
6.03Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 14, 2022
|% Change Since: -9.06%
|Next Earnings Date:Nov 15, 2021
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial and strategic position for Roivant, with significant positive developments in clinical data and capital acquisition. However, challenges remain in prescription growth for VTAMA and pressure on strategic capital use.Company Guidance
During the Roivant Q2 2024 earnings call, several key metrics and guidance highlights were discussed. The company reported $18.4 million in revenue for the quarter, with a gross-to-net (GTN) yield of 27.6%, and anticipates this yield to improve steadily over time. Roivant also shared plans regarding the sale of its Telavant program to Roche for $7.1 billion upfront, with $5.2 billion in expected cash proceeds and an additional $110 million milestone pending. This transaction positions Roivant with $7 billion in pro forma cash and cash equivalents, providing a robust capital base to support further strategic initiatives. The company expressed optimism about the VTAMA commercial launch, despite script volume growing slower than desired, and highlighted the significant growth opportunity with the upcoming atopic dermatitis launch. Furthermore, Roivant emphasized its commitment to being "ruthlessly economic" in its approach to capital deployment, with plans to be patient and strategic in leveraging its pipeline and capital resources, particularly in its FcRn and brepocitinib programs.Record Capital Position
Sale of Telavant to Roche for $7.1 billion upfront and a $110 million milestone, leading to an expected cash and cash equivalents of $7 billion for Roivant.
Strong Clinical Data Delivery
Positive Phase III data for VTAMA in atopic dermatitis and extraordinary clinical data for RVT-3101 in ulcerative colitis.
Positive Progress with IMVT-1402
Initial data from the IMVT-1402 healthy volunteers study suggest a potentially best-in-class anti-FcRn antibody with significant IgG suppression.
VTAMA Commercial Launch Success
VTAMA continues to be the best launching topical in history, with $18.4 million in revenue for the quarter.
Strategic Partnerships and Future Opportunities
Pfizer retains commercial rights outside the U.S. and Japan, with plans for thoughtful capital deployment and potential for new transactions.
---
ROIV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ROIV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $11.81 | $11.64 | -1.44% |
| Aug 08, 2024 | $10.17 | $10.85 | +6.69% |
| May 30, 2024 | $10.73 | $10.39 | -3.17% |
| Feb 13, 2024 | $10.87 | $10.80 | -0.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Roivant Sciences Ltd. (ROIV) report earnings?
Roivant Sciences Ltd. (ROIV) is schdueled to report earning on Feb 17, 2025, TBA Not Confirmed.
What is Roivant Sciences Ltd. (ROIV) earnings time?
Roivant Sciences Ltd. (ROIV) earnings time is at Feb 17, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ROIV EPS forecast?
ROIV EPS forecast for the fiscal quarter 2024 (Q3) is -0.25.
---